Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 14
Treatment-assignment count: 0
Stratification count: 2
NSCLC · Therapy Not Normalized
PD-L1 expression is flagged as manual review required because public trials show inclusion required evidence in 27 contexts. FDA CDx context exists. Threshold text varies across public records.
Strongest role: Inclusion Required
Inclusion-required count: 14
Treatment-assignment count: 0
Stratification count: 2
Threshold count: 15
Common snippets: PD-L1 TPS ≥ 1% | BRAF V600E | KRAS G12C
Threshold label: Fragmented
CDx label: Fda Cdx Context Exists
CDx maturity score: 5/5
Confidence: Low
Signal count: 1
Recent signals: 1
Density label: Low
https://clinicaltrials.gov/study/NCT05089734 | https://clinicaltrials.gov/study/NCT07291037 | https://clinicaltrials.gov/study/NCT04795713 | https://clinicaltrials.gov/study/NCT05527808 | https://clinicaltrials.gov/study/NCT03452592 | https://clinicaltrials.gov/study/NCT06221670 | https://clinicaltrials.gov/study/NCT06311981 | https://clinicaltrials.gov/study/NCT06081907 | https://clinicaltrials.gov/study/NCT03856411 | https://clinicaltrials.gov/study/NCT05487391 | https://clinicaltrials.gov/study/NCT07438600 | https://clinicaltrials.gov/study/NCT04302025 | https://clinicaltrials.gov/study/NCT06300177 | https://clinicaltrials.gov/study/NCT07286149 | https://clinicaltrials.gov/study/NCT04006301 | https://clinicaltrials.gov/study/NCT02716038 | https://clinicaltrials.gov/study/NCT03447769 | https://clinicaltrials.gov/study/NCT04436406 | https://clinicaltrials.gov/study/NCT03030131 | https://clinicaltrials.gov/study/NCT02869685 | https://clinicaltrials.gov/study/NCT06865339 | https://clinicaltrials.gov/study/NCT05465733 | https://clinicaltrials.gov/study/NCT07534033 | https://clinicaltrials.gov/study/NCT06966583 | https://clinicaltrials.gov/study/NCT05445843 | https://clinicaltrials.gov/study/NCT02983578 | https://clinicaltrials.gov/study/NCT04392505